How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades.

We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Milton C. Ault III, insider at Alzamend Neuro

Milton C. Ault III Insider Information

Major Shareholder of Alzamend Neuro
Milton C. (Todd) Ault III founded our company and has served as our Chairman of the Board since inception and as our Executive Chairman since November 2018. As of June 10, 2021, Mr. Ault serves as our Chairman Emeritus. Mr. Ault is a seasoned business professional and entrepreneur who has spent more than 27 years identifying value in various financial markets including equities, fixed income, commodities and real estate. In March 2017, Mr. Ault was appointed Executive Chairman of the Board of Ault Global, in December 2017, Mr. Ault was appointed Chief Executive Officer of Ault Global and, on January 12, 2021, Mr. Ault resumed his title of Executive Chairman. Mr. Ault has served as Chairman of Ault & Company, a holding company since December 2015, and as Chairman of Avalanche International Corp., a publicly traded company (“Avalanche”), since September 2014. Since January 2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Mr. Ault has consulted with many publicly traded and privately held companies, which range from development stage to mature businesses, providing each of them the benefit of his diversified experience.

What is Milton C. Ault III's net worth?

The estimated net worth of Milton C. Ault III is at least $9.04 million as of May 12th, 2022. Mr. Ault III owns 9,791,667 shares of Alzamend Neuro stock worth more than $9,037,709 as of May 17th. This net worth approximation does not reflect any other investments that Mr. Ault III may own. Learn More about Milton C. Ault III's net worth.

How old is Milton C. Ault III?

Mr. Ault III is currently 52 years old. There are 5 older executives and no younger executives at Alzamend Neuro. The oldest executive at Alzamend Neuro is Mr. Kenneth S. Cragun CPA, Sr. VP of Fin., who is 61 years old. Learn More on Milton C. Ault III's age.

How do I contact Milton C. Ault III?

The corporate mailing address for Mr. Ault III and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6333. Learn More on Milton C. Ault III's contact information.

Has Milton C. Ault III been buying or selling shares of Alzamend Neuro?

Within the last three months, Milton C. Ault III has bought $4,255,250.50 in Alzamend Neuro stock. Most recently, on Thursday, May 12th, Milton C. Ault III bought 25,000 shares of Alzamend Neuro stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $21,250.00. Following the completion of the transaction, the insider now directly owns 9,791,667 shares of the company's stock, valued at $8,322,916.95. Learn More on Milton C. Ault III's trading history.

Who are Alzamend Neuro's active insiders?

Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.

Are insiders buying or selling shares of Alzamend Neuro?

During the last year, Alzamend Neuro insiders bought shares 40 times. They purchased a total of 6,762,031 shares worth more than $18,148,453.66. During the last year, insiders at the sold shares 4 times. They sold a total of 51,000 shares worth more than $900,160.00. The most recent insider tranaction occured on May, 12th when Major Shareholder Milton C Ault III bought 25,000 shares worth more than $21,250.00. Learn More about insider trades at Alzamend Neuro.

Information on this page was last updated on 5/12/2022.

Milton C. Ault III Insider Trading History at Alzamend Neuro

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy25,000$0.85$21,250.009,791,667View SEC Filing Icon  
5/5/2022Buy100,000$1.07$107,000.00325,000View SEC Filing Icon  
4/26/2022Buy2,666,667$1.50$4,000,000.509,666,667View SEC Filing Icon  
4/22/2022Buy75,000$0.94$70,500.00225,000View SEC Filing Icon  
4/11/2022Buy50,000$1.13$56,500.00150,000View SEC Filing Icon  
3/18/2022Buy100,000$1.10$110,000.00View SEC Filing Icon  
2/24/2022Buy22,500$1.15$25,875.00View SEC Filing Icon  
1/27/2022Buy2,500$1.40$3,500.00View SEC Filing Icon  
1/24/2022Buy5,000$1.29$6,450.00View SEC Filing Icon  
1/18/2022Buy7,000$1.66$11,620.00View SEC Filing Icon  
1/14/2022Buy3,000$1.79$5,370.00View SEC Filing Icon  
1/7/2022Buy3,000$1.93$5,790.00View SEC Filing Icon  
1/5/2022Buy2,000$1.98$3,960.00View SEC Filing Icon  
12/23/2021Buy1,612$2.10$3,385.20View SEC Filing Icon  
12/20/2021Buy25,000$2.11$52,750.00View SEC Filing Icon  
12/17/2021Buy13,000$2.48$32,240.00View SEC Filing Icon  
11/30/2021Buy5,319$2.27$12,074.13View SEC Filing Icon  
11/22/2021Buy15,000$1.90$28,500.00View SEC Filing Icon  
11/8/2021Buy145,000$2.57$372,650.00View SEC Filing Icon  
9/14/2021Buy5,000$2.70$13,500.00150,000View SEC Filing Icon  
8/27/2021Buy6,000$2.90$17,400.00View SEC Filing Icon  
8/17/2021Buy4,000$3.29$13,160.00View SEC Filing Icon  
8/12/2021Buy3,400$3.87$13,158.00View SEC Filing Icon  
8/9/2021Buy500$4.05$2,025.00View SEC Filing Icon  
8/6/2021Buy4,000$4.07$16,280.00View SEC Filing Icon  
8/4/2021Buy500$4.30$2,150.00View SEC Filing Icon  
8/2/2021Buy1,500$4.56$6,840.00View SEC Filing Icon  
7/30/2021Buy1,338,333$1.51$2,020,882.83View SEC Filing Icon  
7/26/2021Buy3,500$4.94$17,290.00View SEC Filing Icon  
7/23/2021Buy5,000$5.76$28,800.00View SEC Filing Icon  
7/19/2021Buy4,000$5.41$21,640.00View SEC Filing Icon  
7/16/2021Buy600$6.23$3,738.00View SEC Filing Icon  
7/14/2021Buy5,000$6.74$33,700.00View SEC Filing Icon  
7/12/2021Buy8,100$6.15$49,815.00View SEC Filing Icon  
7/8/2021Buy2,000$6.08$12,160.00View SEC Filing Icon  
7/6/2021Buy7,000$7.07$49,490.00View SEC Filing Icon  
6/28/2021Buy9,000$9.61$86,490.00View SEC Filing Icon  
6/25/2021Buy14,000$8.79$123,060.00View SEC Filing Icon  
See Full Table

Milton C. Ault III Buying and Selling Activity at Alzamend Neuro

This chart shows Milton C Ault III's buying and selling at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Company Overview

Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $0.92
Low: $0.90
High: $0.98

50 Day Range

MA: $1.05
Low: $0.88
High: $1.35

2 Week Range

Now: $0.92
Low: $0.80
High: $33.55


432,422 shs

Average Volume

1,016,499 shs

Market Capitalization

$83.16 million

P/E Ratio


Dividend Yield



The U.S. Solution to China's Copper Grab
China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now.
Find Out Where This Copper Hotspot Is